Literature DB >> 32342824

MicroRNAs as Biomarker for Breast Cancer.

Taru Aggarwal1, Ridhima Wadhwa2, Riya Gupta1, Keshav Raj Paudel3, Trudi Collet4, Dinesh Kumar Chellappan5, Gaurav Gupta6, Haribalan Perumalsamy7, Meenu Mehta2, Saurabh Satija2, Philip M Hansbro3, Kamal Dua2, Pawan Kumar Maurya8.   

Abstract

Regardless of advances in detection and treatment, breast cancer affects about 1.5 million women all over the world. Since the last decade, genome-wide association studies (GWAS) have been extensively conducted for breast cancer to define the role of miRNA as a tool for diagnosis, prognosis and therapeutics. MicroRNAs are small, non-coding RNAs that are associated with the regulation of key cellular processes such as cell multiplication, differentiation, and death. They cause a disturbance in the cell physiology by interfering directly with the translation and stability of a targeted gene transcript. MicroRNAs (miRNAs) constitute a large family of non-coding RNAs, which regulate target gene expression and protein levels that affect several human diseases and are suggested as the novel markers or therapeutic targets, including breast cancer. MicroRNA (miRNA) alterations are not only associated with metastasis, tumor genesis but also used as biomarkers for breast cancer diagnosis or prognosis. These are explained in detail in the following review. This review will also provide an impetus to study the role of microRNAs in breast cancer. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.

Entities:  

Keywords:  breast cancer; drug resistance; drug targeting; micro-RNA; oncomirs; oncosuppressormir

Year:  2020        PMID: 32342824     DOI: 10.2174/1871530320666200428113051

Source DB:  PubMed          Journal:  Endocr Metab Immune Disord Drug Targets        ISSN: 1871-5303            Impact factor:   2.895


  3 in total

1.  Differences in plasma microRNA content impair microRNA-based signature for breast cancer diagnosis in cohorts recruited from heterogeneous environmental sites.

Authors:  Jeanne P Uyisenga; Ahmed Debit; Christophe Poulet; Pierre Frères; Aurélie Poncin; Jérôme Thiry; Leon Mutesa; Guy Jerusalem; Vincent Bours; Claire Josse
Journal:  Sci Rep       Date:  2021-06-03       Impact factor: 4.379

2.  Long Non-Coding RNA PVT1 Regulates the Resistance of the Breast Cancer Cell Line MDA-MB-231 to Doxorubicin via Nrf2.

Authors:  Ying Luo; Wei Zhang; Liang Xu; Yajun Chen; Yao Xu; Lin Yuan
Journal:  Technol Cancer Res Treat       Date:  2020 Jan-Dec

Review 3.  Drug Metabolism for the Identification of Clinical Biomarkers in Breast Cancer.

Authors:  Bárbara Costa; Nuno Vale
Journal:  Int J Mol Sci       Date:  2022-03-16       Impact factor: 5.923

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.